Navan Moves Toward IPO With Confidential SEC Filing
Navan, a business travel tech company, said Friday it has filed with the U.S. Securities and Exchange Commission for a proposed IPO – but it was a "confidential" submission and no financial details were publicly available.
'The number of shares to be offered and the price range for the proposed offering have not yet been determined,' the company said.
The company was last valued at $9.2 billion during its series G venture capital raise in October 2022, a time when many private valuations were considered inflated.
The IPO market has been unusually slow, but analysts believe that several offerings in recents weeks signal that the market is heating up.
Navan is a corporate travel agency with a tech platform where employees at client companies can complete bookings and manage expenses. Clients include Lyft, Wayfair, Toast, Thomson Reuters, Zoom, Shopify, and more.
Navan CEO Ariel Cohen in May 2024 said the company was "not far" from an IPO, though he noted the timing could be affected by market conditions and geopolitical factors outside the company's control.
The company has hired two execs with IPO experience over the past year.
Amy Butte joined Navan as chief financial officer last June, and was previously CFO at the New York Stock Exchange during its IPO. Rich Liu, an early chief revenue officer for Navan, returned to the company as CEO of Navan Travel. Liu previously helped two companies go public.
Cohen and CTO Ilan Twig founded Navan in 2015. The company now has more than 3,000 employees and more than 10,000 clients, according to its website.
The company has raised well over $1 billion in venture capital.
Business travel tech platforms have been gaining traction as companies have been looking to streamline various operations post-pandemic. TravelPerk has raised over $700 million, most recently $200 million in January. Expense management platform Ramp has raised over $2 billion, with reports that it's seeking more funding at a valuation of $16 billion. Several others have been raising money to target their respective geographic regions.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
AstraZeneca unveils $50 billion US investment as pharma tariff threat looms
By Maggie Fick and Ahmed Aboulenein WASHINGTON (Reuters) -AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on Monday, the latest big investment by a pharmaceutical company reacting to President Donald Trump's tariff policy. The investment will fund a new drug manufacturing facility in Virginia and expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, it said in a statement. It will also upgrade the Anglo-Swedish drugmaker's U.S. clinical trial supply network and support ongoing investment in novel medicines. On Monday, AstraZeneca said the expansion supports its ambition to reach $80 billion in annual revenue by 2030, with half coming from the U.S. The U.S. accounted for more than 40% of AstraZeneca's annual revenue in 2024, and the company had been prioritising the market - the world's largest, worth $635 billion - before Trump's return to office. The move to scale up its U.S. footprint is the latest by a drugmaker as Trump threatens to impose import tariffs on the industry and seeks to boost domestic manufacturing. The sector has historically been spared from trade disputes. Trump has called on pharma companies to make more of the medicines they sell in the U.S. within the country, rather than importing active ingredients or finished medicines. CEO Pascal Soriot announced the plans in Washington. U.S. Commerce Secretary Howard Lutnick's department is leading a probe into pharmaceutical imports that could pave the way for new tariffs. "For decades Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation's new tariff policies are focused on ending this structural weakness," said Lutnick in a statement issued by AstraZeneca. While Trump has repeatedly threatened tariffs on the sector, he signalled earlier this month that companies would be given a year to 18 months to "get their act together" before any levies take effect. The company said that the timing and location of the announcement was linked to the U.S. policy environment, though some of the spending would have occurred regardless so that the infrastructure for future medicines was in place. The pledge is in addition to the $3.5 billion in investments the company announced in November 2024, the statement said. PLEDGES The $50 billion pledge matches the commitment announced by Swiss rival Roche in April and exceeds new spending plans unveiled this year by Eli Lilly & Co, Johnson & Johnson, Novartis, and Sanofi. Also present at the announcement was Virginia State Governor Glenn Youngkin, a vocal Trump ally who has defended the administration's tariff policies. The new Virginia facility - the company's largest single manufacturing investment - will produce active ingredients for AstraZeneca's experimental weight-loss medicines, including its oral GLP-1 candidate and an oral PCSK9 inhibitor for cholesterol management, it said. The company said the investment could create tens of thousands of new jobs, but declined to give specifics. It employs about 18,000 people in the U.S. and has a global workforce of about 90,000. The effort to strengthen its U.S. ties comes after years of criticism of the UK business investment climate. In January it scrapped plans to invest 450 million pounds ($607.1 million) in its vaccine manufacturing plant in northern England, citing a cut in government support. Earlier this month, The Times reported the company was considering moving its stock market listing from London, where it is the exchange's most valuable company worth 159 billion pounds, to the U.S. The company declined to comment. The company rejoined the leading U.S. drug lobby group earlier this year, roughly two years after leaving it. ($1 = 0.7415 pounds) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Jerry Jones says he'll remain as Cowboys GM and 'nothing new' in Micah Parsons contract talks
OXNARD, Calif. (AP) — Given that the Dallas Cowboys have gone 29 seasons since appearing in an NFC championship game — the longest drought in the conference — owner Jerry Jones has found himself occasionally considering whether to step down as general manager. 'Yes, momentary,' Jones said Monday. 'Small fractions of seconds, I promise you.' With his player personnel duties seemingly not changing anytime soon, Jones remains focused on how to get the Cowboys back to the Super Bowl. That seems unlikely to happen anytime soon without a happy, healthy and productive Micah Parsons in the fold, and the star defender's contract dispute was primary topic of discussion Monday before the start of training camp. 'There's nothing new about what we're talking about here today relative to contracts. That's been going on a long time now,' Jones said. 'If you say, well, if you don't get him in you're going to lose the first two games, then go on to win the Super Bowl, well, we'll take that,' he continued, referencing running back Emmitt Smith's 1993 holdout. There were no updates on Parsons' on-field status from Jones, executive vice president of personnel Stephen Jones or new coach Brian Schottenheimer ahead of the team's annual, nearly monthlong stop in Ventura County. It's the second straight offseason where financial dealings with standout players risk overshadowing the Cowboys' football preparations. Quarterback Dak Prescott participated in training camp last year before getting a new contract before the start of the season that made him the NFL's highest-paid player. Wide receiver CeeDee Lamb held out of camp before receiving a new $136 million, four-year contract with $100 million guaranteed last August. Those protracted dealings came ahead of a 7-10 season that marked the end of Mike McCarthy's five-year run as coach. Parsons had 12 sacks and 12 tackles for loss in 13 games, the lowest tallies of his four seasons in Dallas in each category. The 26-year-old defensive end is at camp, something the elder Jones appreciates, but it isn't clear if Parsons will participate in the first practice on Tuesday. He is going into the fifth and final year of his rookie contract, and the Cowboys would be able to able to apply the franchise tag in 2026. Jones said he had not negotiated directly with Parsons' agent, David Mulugheta, though Stephen Jones later clarified that he is typically the one who might handles such discussions. 'Obviously, we don't have a deal with Micah, and we have work to do. That's the only thing I would comment on,' Stephen Jones said when asked what was holding up a potential deal that will almost certainty make Parsons the league's highest-paid defender. Jerry Jones doesn't believe a likely Parsons hold-in would impact the team's development during camp, which runs through Aug. 14. 'I'm not concerned at all about what our team can be this year, and develop and develop into, and what we make of our training camp,' Jones said. 'I'm not at all concerned about a contract that involves and will affect that in any way, I can't emphasize that enough.' The ever-loquacious Jones alternated between praising Parsons' business acumen and pointing out he dealt with an injury for the first time in his career, missing four games because of a high ankle sprain, during a typically freewheeling hourlong news conference. The 82-year-old Jones said he still enjoys making player personnel decisions, even against the backdrop of constant criticism as the Cowboys have won five playoff games in the past 29 seasons. 'I like it this way, and if you watch this (upcoming documentary on) Netflix, you'll see I gave every frigging thing in my life and then exposed probably two or three times that to get to sit up here,' Jones said. 'Listen, listen, I haven't worked in 35 years,' Jones added later. 'I've had the damnedest run and the most fun that you could ever imagine.' That includes a memorable recent cameo in the streaming series 'Landman.' Appearing as himself opposite actors Billy Bob Thornton and Jon Hamm to deliver a monologue about the importance of including family in his business pursuits, Jones joked the filmmakers cut the best take of an off-color joke he tells during a hospital room conversation with Hamm's stricken oil baron. 'They took that out, and I thought it was the best scene in the whole thing,' Jones said. ___ AP NFL:
Yahoo
13 minutes ago
- Yahoo
S&P 500 Gains and Losses Today: Verizon Shares Surge; Natural Gas Stocks Fall
Major indexes posted modest gains Monday as investors prepared for a major wave of earnings reports set for release throughout the week, including results from big names such as Tesla (TSLA) and Coca-Cola (KO). The S&P 500 gained 0.1%, reaching an all-time closing high as the new trading week got underway. The Nasdaq added 0.4%, extending an impressive streak of record closes that dates back to the beginning of last week. After trading in positive territory for most of the session, the Dow lost ground in the afternoon to close with a minor loss. Verizon Communications (VZ) shares jumped 4%, gaining the most of any stock in the S&P 500. The telecommunications giant topped second-quarter sales and profit estimates and lifted the low end of the range for its full-year profit forecast. Stronger-than-expected gains in broadband internet subscribers and an increase in wireless retail core prepaid customers helped drive Verizon's strong quarterly performance. Hershey (HSY) shares gained 3.2% on Monday, adding to gains posted late last week after U.S. Census Bureau data showed a stronger-than-expected uptick in retail sales in June. The indication of sustained consumer spending despite tariff concerns represents a welcome demand signal for the chocolate maker, which has been navigating challenges related to high cocoa prices. Gold prices reached their highest level in more than a month, boosted by a weakening U.S. dollar, uncertainty ahead of President Trump's Aug. 1 tariff deadline, and anticipation of the Fed potentially edging toward interest-rate cuts later in the year. Shares of Newmont (NEM), the world's largest gold mining company, advanced 2.9%. Shares of Google parent Alphabet (GOOGL) were up 2.7% ahead of the tech giant's quarterly earnings release, set for Wednesday afternoon. Analysts at Morgan Stanley and Bank of America lifted their price targets on Alphabet stock ahead of the report, highlighting growth expectations driven by generative AI and ad spending in Google search. Natural gas futures prices dropped around 7%, pressured by elevated production levels and forecasts for cooler summer temperatures in parts of the U.S., reducing demand for natural gas to power air conditioners. Shares of natural gas companies dominated the list of the S&P 500's weakest performers on Monday. EQT Corp. (EQT) stock dropped 9.5%, falling the furthest of any constituent in the benchmark index. Expand Energy (EXE) shares were down 8.5%, while fellow natural gas players Coterra Energy (CTRA) and Targa Resources (TRGP) also lost ground. Shares of Molina Healthcare (MOH) lost 3.6% after analysts at TD Cowen cut their price target on the insurer's stock. Analysts also reduced their full-year earnings estimate for Molina, noting that high medical costs are pressuring the company's medical loss ratio, or the percentage of premiums an insurer pays out on healthcare claims. The slide for Molina stock on Monday extended steep losses posted late last week after competitor Elevance Health (ELV) cut its full-year guidance, citing high Medicaid and Affordable Care Act costs. Read the original article on Investopedia
